手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
4条
与
Phosphodiesterase 5 inhibitor
有关的结果
Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha-blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis
2020年 发布于
Urological Science
31卷 第3期
Chen
P. C. Wang
C. C. Tu
Y. K.
Alpha blocker and phosphodiesterase 5 inhibitor
Alpha-blocker monotherapy
benign prostate hyperplasia
systematic review
meta-analysis
文献简介
原文链接
The hemodynamic interactions of combination therapy with α-blockers and phosphodiesterase-5 inhibitors compared to monotherapy with α-blockers: a systematic review and meta-analysis
2020年 发布于
Int Urol Nephrol
52卷 第8期
Adamou
C. Ntasiotis
P. Athanasopoulos
A. Kallidonis
P.
Adrenergic alpha-Antagonists/*administration & dosage/pharmacology
Drug Interactions
Drug Therapy
Combination
Erectile Dysfunction/complications/*drug therapy/physiopathology
Hemodynamics/*drug effects
Humans
Lower Urinary Tract Symptoms/complications/*drug therapy/physiopathology
Male
Phosphodiesterase 5 Inhibitors/*administration & dosage/pharmacology
Prostatic Hyperplasia/complications/*drug therapy/physiopathology
Randomized Controlled Trials as Topic
Alpha blocker
Benign prostatic hyperplasia
Erectile dysfunction
Hemodynamic interaction
Luts
Phosphodiesterase-5 inhibitors
文献简介
原文链接
Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review
2019年 发布于
Aging Male
22卷 第1期
MacDonald
R. Brasure
M. Dahm
P. Olson
C. M. Nelson
V. A. Fink
H. A. Risk
M. C. Rwabasonga
B. Wilt
T. J.
Adrenergic alpha-1 Receptor Antagonists/*administration & dosage
Adrenergic beta-3 Receptor Agonists/administration & dosage
Cholinergic Antagonists/administration & dosage
Drug Therapy
Combination
Humans
Lower Urinary Tract Symptoms/*drug therapy
Male
Phosphodiesterase 5 Inhibitors/*administration & dosage
Prostatic Hyperplasia/complications
Quality of Life
Randomized Controlled Trials as Topic
5-alpha reductase inhibitor
Lower urinary tract symptoms
alpha blockers
anticholinergic: systematic review
benign prostatic hyperplasia
randomized trials
文献简介
原文链接
Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression
2018年 发布于
Int Urol Nephrol
50卷 第1期
Sun
H. Y. Lee
B. Kim
J. H.
Humans
Lower Urinary Tract Symptoms
Male
Phosphodiesterase 5 Inhibitors/administration & dosage/adverse
effects
Placebos
Prostatic Hyperplasia/complications/*etiology
Quality of Life
Regression Analysis
Severity of Illness Index
Lower urinary tract symptoms
Meta-analysis
Phosphodiesterase 5 inhibitor
Placebo
Prostatic hyperplasia
文献简介
原文链接